Agilent Technologies Inc vs iShares Core S&P 500 ETF — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while iShares Core S&P 500 ETF trades at $774.81. The key difference: Agilent Technologies Inc pays a 0.69% dividend while iShares Core S&P 500 ETF pays none, and iShares Core S&P 500 ETF is trading nearer its 52-week high, Agilent Technologies Inc nearer its low. Which is the better fit depends on your goals.
| A | IVV | |
|---|---|---|
Market Cap | $42.00B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $157.20 | $776.81 |
52-Week Low | $110.24 | $634.93 |
Enterprise Value | $43.55B | — |
Dividend Yield | 0.69% | — |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
IVV, tracking the S&P 500, trades at $776.81, up 0.6% with a bullish technical signal from moving averages. The ETF approaches resistance near $779-$784 amid strong institutional interest, including a 24.8% position increase by First Bank & Trust. Recent news highlights record highs and JPMorgan's raised 2026 target to 8,000, driven by AI-fueled earnings growth.
Outlook remains positive with S&P 500 earnings growth up 51.1% year-over-year, but risks include overbought conditions (RSI_6 at 94.32) and potential consolidation. Investor sentiment is greedy, yet weak market breadth and high valuations warrant caution for near-term volatility.
Trailing returns across standard periods
Latest headlines on both assets
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →